Meda has signed an agreement to acquire Alaven, a U.S.-based specialty pharmaceutical company. The acquisition is intended to enhance Meda’s marketing capabilities in the U.S. and expand its therapeutic focus to include both gastroenterology and women’s health, both areas that Meda operates in outside of the U.S. Alaven also has a strategic OTC platform that accounts for approximately 25% of sales. The OTC business will further diversify Meda’s revenue base in the U.S., as well as serve as a ...